Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis

Abstract

This study aimed to provide information that bedaquilline is significantly effective for treatment of totally drug resistant (TDR) Mycobacterium tuberculosis that shows resistant to all first- and second-line drugs-using an innovative disc agarose channel (DAC) system. Time-lapse images of single bacterial cells under culture conditions with different concentrations of bedaquiline were analysed by image processing software to determine minimum inhibitory concentrations (MICs). Bedaquiline inhibited the growth of TDR M. tuberculosis strains, with MIC values ranging from 0.125 to 0.5 mg/L. The results of the present study demonstrate that bedaquiline, newly approved by the United States Food and Drug Administration (FDA), may offer therapeutic solutions for TDR-TB.

Sudapyridine (WX-081), a Novel Compound against Mycobacterium tuberculosis

“…Moreover, WX-081 and BDQ achieved almost equivalent efficacies against 15 drug-resistant TB strains with the MIC in the range of 0.026 to 0.966 μg/mL. The results are consistent with previous studies ( 15 , 16 ). On the other hand, WX-081 had some bactericidal activity but had a weak direct bactericidal effect on drug-resistant MTB, a similar effect as BDQ.…”

In vitro activity of bedaquiline against Mycobacterium avium complex

“…Bdq effects on M. tuberculosis have been well studied in vitro [43–46]. As shown above, such studies are also conducted with respect to the effect of Bdq on NTM, in particular MAC (including the results of this study).…”